BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $12.00 Price Target at Evercore ISI

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lifted by equities researchers at Evercore ISI from $10.00 to $12.00 in a report released on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s target price would indicate a potential upside of 57.27% from the stock’s previous close.

Several other research analysts also recently issued reports on BCRX. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC raised their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $15.17.

BioCryst Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ BCRX traded down $0.04 during midday trading on Monday, hitting $7.63. The stock had a trading volume of 398,222 shares, compared to its average volume of 2,139,550. The stock has a 50 day simple moving average of $7.59 and a 200-day simple moving average of $7.59. The company has a market capitalization of $1.58 billion, a PE ratio of -12.51 and a beta of 1.76. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the company earned ($0.19) EPS. As a group, analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of BCRX. Mirae Asset Global Investments Co. Ltd. boosted its position in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Quantinno Capital Management LP acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at $82,000. DRW Securities LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $74,000. Xponance Inc. boosted its stake in BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,505 shares during the period. Finally, SkyView Investment Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.